The acquisition will unite complementary leading AI-powered cancer detection and workflow solutions focused on improving the accuracy and early detection of breast cancer

此次收购将整合互补的领先人工智能癌症检测和工作流程解决方案，专注于提高乳腺癌检测的准确性和早期发现。

The transaction is expected to add to RadNet’s wholly owned subsidiary, DeepHealth, an installed base of over 1,500 healthcare provider locations across over 50 countries

该交易预计将为RadNet的全资子公司DeepHealth增加超过1,500个医疗机构地点的安装基础，覆盖超过50个国家。

With iCAD’s seasoned commercial and engineering team anticipated to join DeepHealth, the combination is expected to accelerate RadNet’s growth and leadership in cancer screening and artificial intelligence

随着iCAD经验丰富的商业和工程团队预计将加入DeepHealth，这一组合有望加速RadNet在癌症筛查和人工智能领域的增长和领导地位。

Following the completion of the acquisition, iCAD will be integrated into RadNet’s DeepHealth portfolio of solutions

收购完成后，iCAD 将被整合到 RadNet 的 DeepHealth 解决方案组合中。

RadNet will host a conference call and webcast at 10:30 a.m. ET tomorrow, April 16, 2025, to discuss the transaction

RadNet 将于东部时间 2025 年 4 月 16 日上午 10 点 30 分举办电话会议和网络直播，讨论该交易。

LOS ANGELES and NASHUA, N.H., April 15, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, and iCAD, Inc. (NASDAQ: ICAD) (“iCAD”), a global leader in providing clinically proven AI-powered breast health solutions, announced today that they have entered into a definitive merger agreement under which RadNet will acquire iCAD in an all stock transaction..

洛杉矶和新罕布什尔州纳舒厄，2025年4月15日（环球新闻社）——RadNet, Inc.（纳斯达克股票代码：RDNT）（“RadNet”），全国领先的高质量、高性价比诊断影像服务和数字健康解决方案提供商，与iCAD, Inc.（纳斯达克股票代码：ICAD）（“iCAD”），全球领先的临床验证AI驱动乳腺健康解决方案提供商，今天宣布已达成一项最终合并协议，根据该协议，RadNet将通过全股票交易收购iCAD。

Under the terms of the merger agreement, iCAD stockholders will receive 0.0677 shares of RadNet common stock for each share of iCAD common stock they hold at the closing of the merger.

根据合并协议的条款，iCAD 股东在合并结束时将为其持有的每一股 iCAD 普通股获得 0.0677 股 RadNet 普通股。

Based upon RadNet’s closing price on Monday, April 14, 2025, this represents a transaction value of approximately $103 million, or approximately $3.61 per share of iCAD common stock on a fully diluted basis and an approximately 98% premium to iCAD stockholders based on iCAD’s closing stock price on Monday, April 14, 2025.   .

基于RadNet在2025年4月14日（星期一）的收盘价，此次交易的价值约为1.03亿美元，相当于每股iCAD普通股在完全稀释基础上约3.61美元，并且根据iCAD在2025年4月14日（星期一）的收盘股价，为iCAD股东带来了约98%的溢价。

Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, “Every 14 seconds, a woman is diagnosed with breast cancer worldwide, and in the United States alone, over 42,000 women are expected to die from breast cancer during 2025. iCAD’s ProFound Breast Health Suite and RadNet’s DeepHealth AI-powered breast screening solutions, together, have the power to materially expand and improve patient diagnosis and outcomes on a global basis through further enabling accuracy and early-detection.

RadNet的总裁兼首席执行官霍华德·伯杰博士评论道：“每14秒，就有一名女性在全球范围内被诊断出患有乳腺癌，仅在美国，预计到2025年将有超过42,000名女性死于乳腺癌。iCAD的ProFound乳腺健康套件和RadNet的DeepHealth人工智能乳腺筛查解决方案相结合，通过进一步提高准确性和早期检测能力，有潜力在全球范围内大幅扩展和改善患者的诊断与治疗结果。”

With over 1,500 healthcare provider locations, facilitating over 8 million annual mammograms in 50 countries, iCAD’s installed base and strong sales, engineering and marketing capabilities will provide us with immediate broad and valuable customer relationships and commercialization capabilities that can accelerate our existing DeepHealth objectives.

iCAD拥有超过1500个医疗保健提供方的网点，遍布50个国家，每年协助完成超过800万次乳腺X光检查。其庞大的安装基础以及强大的销售、工程和营销能力，将为我们带来广泛且宝贵的客户关系和商业化能力，有助于加速我们现有的DeepHealth目标。

This business combination is expected to accelerate our global leadership and commitment to AI-powered breast cancer screening, and positions us to further advance population health.”.

这项业务合并预计将加速我们在人工智能驱动的乳腺癌筛查方面的全球领导地位和承诺，并使我们能够进一步促进人口健康。

Dana Brown, President and CEO of iCAD added, “As we join forces with RadNet to create a broad offering of AI-driven solutions, we have the opportunity to redefine how breast cancer and other diseases are detected and treated. Together, we will work to expand access to cutting-edge tools, accelerate innovation and advance our product roadmaps, empowering radiologists with more precise, efficient and scalable solutions that should ultimately improve patient care and outcomes.

iCAD总裁兼首席执行官达纳·布朗补充道：“随着我们与RadNet联手打造广泛的AI驱动解决方案，我们有机会重新定义乳腺癌和其他疾病的检测与治疗方法。我们将共同努力，扩展尖端工具的使用范围，加速创新并推进我们的产品路线图，为放射科医生提供更精准、高效和可扩展的解决方案，最终改善患者护理和治疗效果。”

With current and future products in breast cancer detection, risk evaluation, density assessment and breast arterial calcification, we believe RadNet’s scale, access to data and clinical leadership will ensure our current and future products are brought to market, improving radiologist and patient workflow and clinical outcomes.”.

通过当前和未来在乳腺癌检测、风险评估、密度评估以及乳腺动脉钙化方面的产品，我们相信RadNet的规模、数据获取能力和临床领导地位将确保我们的当前和未来产品顺利进入市场，改善放射科医生和患者的工作流程及临床结果。

The transaction, expected to close in the second or third quarter of 2025, is subject to approval by iCAD stockholders and other customary closing conditions, and was unanimously approved by each company’s board of directors.

该交易预计将在 2025 年第二或第三季度完成，但须经 iCAD 股东批准并满足其他惯例成交条件，并已获得两家公司董事会的一致通过。

RadNet will host an investor conference call and webcast tomorrow, April 16, 2025, at 10:30 AM Eastern Time / 7:30 AM Pacific Time to discuss the details of the transaction. Associated materials regarding the transaction will be available on the investor relations section of each company's website.

RadNet 将于 2025 年 4 月 16 日东部时间上午 10 点 30 分 / 太平洋时间上午 7 点 30 分举办投资者电话会议和网络直播，讨论该交易的详细信息。与本次交易相关的材料将发布在每家公司网站的投资者关系部分。

Conference Call Details:

电话会议详情：

Date: April 16, 2025

日期：2025年4月16日

Time: 10:30 a.m. ET / 7:30 a.m. PT

时间：东部时间上午10:30 / 太平洋时间上午7:30

Dial In-Number: 844-826-3035

拨入号码：844-826-3035

International Dial-In Number: 412-317-5195

国际拨入号码：412-317-5195

There will also be simultaneous and archived webcasts available at

同时还将提供同步和存档的网络直播，可访问以下网址

https://viavid.webcasts.com/starthere.jsp?ei=1716330&tp_key=176fbd27c7

https://viavid.webcasts.com/starthere.jsp?ei=1716330&tp_key=176fbd27c7

or

或

http://www.radnet.com

http://www.radnet.com

under the “About RadNet” menu section and “News & Press Releases” sub-menu of the website. An archived replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international callers, and using the passcode 10199100.

在网站的“关于RadNet”菜单部分和“新闻与新闻稿”子菜单中。此次电话会议的存档重播也将提供，可以通过拨打美国国内电话844-512-2921或国际电话412-317-6671并使用密码10199100来访问。

Perkins Coie LLP and Reed Smith LLP are serving as legal counsel to RadNet in connection with the transaction. Piper Sandler & Co. is serving as financial advisor to iCAD and Dentons LLP is serving as iCAD’s legal counsel.

泛伟律师事务所和里德·史密斯律师事务所担任RadNet本次交易的法律顾问。Piper Sandler & Co. 担任iCAD的财务顾问，大成律师事务所担任iCAD的法律顾问。

About RadNet

关于RadNet

RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 398 owned and/or operated outpatient imaging centers. RadNet’s markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas.

RadNet, Inc. 是美国基于地点数量和年度影像收入的领先全国性独立固定式诊断影像服务提供商。RadNet 拥有和/或运营一个由 398 个门诊影像中心组成的网络。RadNet 的市场包括亚利桑那州、加利福尼亚州、特拉华州、佛罗里达州、马里兰州、新泽西州、纽约州和德克萨斯州。

In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 11,000 employees.

此外，RadNet 还提供以 DeepHealth 品牌销售的放射科信息技术和人工智能解决方案、远程放射科专业服务以及其他相关产品和服务，面向诊断影像行业的客户。加上签约的放射科医生，包括全职和按日计酬的员工及技术人员在内，RadNet 共有超过 11,000 名员工。

For more information, visit http://www.radnet.com.  .

欲了解更多信息，请访问 http://www.radnet.com。

About iCAD

关于iCAD

iCAD is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation.

iCAD是一家全球领先的公司，致力于通过提供经过临床验证的AI驱动解决方案，创造一个癌症无法隐藏的世界，使医疗机构能够更早、更准确、更可靠地检测癌症并改善患者预后。总部位于新罕布什尔州纳舒厄，iCAD行业领先的ProFound乳腺健康套件为乳腺癌检测、密度评估和风险评估提供了AI驱动的乳腺X线摄影分析。

Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis. For more information, including the latest in regulatory clearances, please visit www.icadmed.com..

ProFound 已被数千家医疗机构使用，服务数百万患者，覆盖全球超过 50 个国家。仅在过去五年中，iCAD 估计已在全球范围内读取超过 4000 万份乳腺 X 光片，其中近 30% 为断层合成影像。欲了解更多信息，包括最新的监管审批情况，请访问 www.icadmed.com。

RADNET CONTACT

雷达网联系

Mark Stolper, 310-445-2800

马克·斯托尔珀，310-445-2800

Executive Vice President and Chief Financial Officer

执行副总裁兼首席财务官

ICAD CONTACT

ICAD联系人

John Nesbett/Rosalyn Christian

约翰·内斯贝特/罗莎琳·克里斯蒂安

IMS Investor Relations

IMS投资者关系

icad@imsinvestorrelations.com

icad@imsinvestorrelations.com

No Offer or Solicitation

无提供或招揽

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

本通讯不构成出售或征求购买任何证券的要约，也不构成征求任何投票或批准，且在根据该司法管辖区的证券法进行注册或资格认证之前，在任何司法管辖区中进行此类要约、征求或出售证券均属违法的情况下，不得在任何司法管辖区进行证券的出售、发行或转让。

It does not constitute a prospectus or prospectus equivalent document. No offering or sale of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the “Securities Act”), and otherwise in accordance with applicable law..

它不构成招股说明书或相当于招股说明书的文件。除根据经修订的《1933年证券法》（“证券法”）第10条要求的招股说明书进行外，不得进行证券的发行或销售，并且须遵守适用法律的规定。

Important Information about the Proposed Transaction and Where to Find It

有关拟议交易的重要信息及查找位置

In connection with the proposed transaction between RadNet and iCAD, RadNet plans to file with the Securities and Exchange Commission (“SEC”) a registration statement on Form S-4 that constitutes a prospectus of RadNet and will also include a proxy statement of iCAD. After the registration statement has been declared effective, iCAD will mail the proxy statement/prospectus to its stockholders.

关于RadNet与iCAD之间拟议的交易，RadNet计划向美国证券交易委员会（“SEC”）提交一份S-4表格的注册声明，该声明构成RadNet的招股说明书，并将包括iCAD的委托书声明。在注册声明生效后，iCAD将向其股东邮寄委托书声明/招股说明书。

The proxy statement/prospectus to be filed with the SEC related to the proposed merger will contain important information about RadNet, iCAD, the proposed transaction and related matters. RadNet and iCAD may also file other documents with the SEC regarding the proposed transaction. This communication is not a substitute for the proxy statement/prospectus or any other document which RadNet or iCAD may file with the SEC.

与拟议合并相关的将向美国证券交易委员会（SEC）提交的代理声明/招股说明书将包含有关RadNet、iCAD、拟议交易及相关事项的重要信息。RadNet和iCAD还可能就拟议交易向SEC提交其他文件。本通信并非代理声明/招股说明书或RadNet或iCAD可能向SEC提交的任何其他文件的替代品。

.

。

Investors are urged to carefully read the proxy statement/prospectus and other documents to be filed with the SEC (or incorporated by reference into the proxy statement/prospectus), as well as any amendments or supplements to these documents, in connection with the proposed transaction, when available, because they will contain important information about the proposed transaction and related matters..

投资者应仔细阅读与拟议交易相关的代理声明/招股说明书以及将要提交给美国证券交易委员会（SEC）的其他文件（或通过引用并入代理声明/招股说明书的文件），以及这些文件的任何修订或补充（在可用时），因为它们将包含有关拟议交易及相关事项的重要信息。

Investors will be able to obtain free copies of the registration statement on Form S-4 and the proxy statement/prospectus (when available), and other documents filed by RadNet or iCAD with the SEC through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by RadNet can be obtained by contacting RadNet’s Investor Relations by telephone at (310) 445-2800 or by mail at 1510 Cotner Avenue, Los Angeles, California 90025.

投资者将能够通过美国证券交易委员会（SEC）维护的网站www.sec.gov免费获取RadNet或iCAD向SEC提交的S-4表格注册声明、代理声明/招股说明书（在可用时）以及其他文件。RadNet向SEC提交的文件副本，可以通过拨打(310) 445-2800联系RadNet的投资者关系部门，或者通过邮寄至加利福尼亚州洛杉矶市科特纳大道1510号（邮编90025）获取。

In addition, investors are able to obtain free copies of the documents filed with the SEC on RadNet’s website at www.radnet.com (which website is not incorporated herein by reference). Copies of the documents filed with the SEC by iCAD can be obtained by contacting iCAD’s Investor Relations by telephone at (608) 882-5200 or by mail at 2 Townsend West, Suite 6, Nashua, New Hampshire 03063.

此外，投资者可以在RadNet的网站www.radnet.com上免费获取提交给美国证券交易委员会的文件副本（该网站并未通过引用纳入本文）。要获取iCAD提交给美国证券交易委员会的文件副本，可以通过电话(608) 882-5200联系iCAD的投资者关系部门，或通过邮寄至新罕布什尔州纳舒厄市西镇路2号6室，邮编03063。

In addition, investors are able to obtain free copies of the documents filed with the SEC on iCAD’s website at www.icadmed.com (which website is not incorporated herein by reference)..

此外，投资者可以在iCAD的网站www.icadmed.com上免费获取提交给美国证券交易委员会的文件副本（该网站并未通过引用并入本文）。

Participants in the Solicitation

征求意见的参与者

RadNet, iCAD and their respective directors and executive officers may be considered participants in the solicitation of proxies from iCAD’s stockholders in connection with the proposed transaction. Information about the directors and executive officers of RadNet is set forth in its proxy statement for its 2024 annual meeting of stockholders, which was filed with the SEC on April 26, 2024.

RadNet、iCAD 及其各自的董事和高级管理人员可能会被视为在拟议交易中向 iCAD 股东征求代理投票的参与者。有关 RadNet 董事和高级管理人员的信息载于其 2024 年股东年会的委托书声明中，该声明已于 2024 年 4 月 26 日提交给美国证券交易委员会 (SEC)。

Information about the directors and executive officers of iCAD is set forth in its proxy statement for its 2024 annual meeting of stockholders, which was filed with the SEC on April 29, 2024. To the extent holdings of RadNet’s or iCAD’s securities by its directors or executive officers have changed since the amounts set forth in such filings, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Beneficial Ownership on Form 4 filed with the SEC.

有关iCAD的董事和高级管理人员的信息载于其2024年年度股东大会的委托书声明中，该声明已于2024年4月29日提交给美国证券交易委员会（SEC）。如果其董事或高级管理人员对RadNet或iCAD证券的持有量自上述文件中列出的数额以来发生了变化，这些变化已经或将在提交给SEC的初始持股声明（表格3）或持股变动声明（表格4）中反映。

Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, and other information regarding the potential participants in the proxy solicitations, which may be different than those of RadNet’s stockholders and iCAD’s stockholders generally, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction.

有关代理征集参与者的信息及其他相关信息，以及他们通过持有证券或其他方式的直接和间接利益的描述，以及其他有关潜在代理征集参与者的信息（可能与RadNet股东和iCAD股东的利益有所不同），将包含在与拟议交易相关的向美国证券交易委员会提交的委托书/招股说明书及其他相关材料中。

You may obtain these documents (when they become available) free of charge through the website maintained by the SEC at http://www.sec.gov and from the investor relations departments at RadNet or iCAD or from RadNet’s website or iCAD’s website, in each case, as described above..

您可以通过美国证券交易委员会 (SEC) 维护的网站 http://www.sec.gov 以及 RadNet 或 iCAD 的投资者关系部门，或从 RadNet 的网站或 iCAD 的网站（在每种情况下，如上所述）免费获取这些文件（当它们可用时）。

Forward-Looking Statements

前瞻性声明

This communication contains certain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as: “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “outlook,” “plan,” “potential,” “possible,” “predict,” “project,” “seek, “should,” “target,” “will” or “would,” the negative of these words, and similar references to future periods.

本通讯包含某些“前瞻性陈述”，这些陈述符合1995年美国私人证券诉讼改革法案、修订后的《证券法》第27A条以及《证券交易法》第21E条中的安全港条款。前瞻性陈述可以通过诸如“预期”、“相信”、“可能”、“估计”、“预计”、“预测”、“打算”、“或许”、“展望”、“计划”、“潜在”、“可能”、“推测”、“预计”、“寻求”、“应该”、“目标”、“将”或“会”等词语，以及这些词语的否定形式和对未来时期的类似引用来识别。

Examples of forward-looking statements include statements regarding the anticipated benefits of the proposed transaction, the impact of the proposed transaction on RadNet’s and iCAD’s business and future financial and operating results and prospects, the amount and timing of synergies from the proposed transaction and the closing date for the proposed transaction are based on the current estimates, assumptions and projections of RadNet and iCAD, and are qualified by the inherent risks and uncertainties surrounding future expectations generally, all of which are subject to change.

前瞻性陈述的示例包括关于拟议交易预期收益的陈述、拟议交易对RadNet和iCAD业务及未来财务和运营结果与前景的影响、拟议交易协同效应的规模和时间，以及拟议交易的完成日期，这些均基于RadNet和iCAD当前的估算、假设和预测，并受制于围绕未来预期的一般性固有风险和不确定性，所有这些都可能发生变化。

Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties, many of which are beyond RadNet’s and iCAD’s control..

由于许多风险和不确定性，实际结果可能与当前预期的结果存在重大差异，其中许多风险和不确定性是RadNet和iCAD无法控制的。

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations and assumptions regarding the future of RadNet’s and iCAD’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions.

前瞻性陈述既不是历史事实，也不是对未来业绩的保证。相反，它们仅基于管理层对RadNet和iCAD业务未来发展的信念、预期和假设，包括未来的计划与战略、预测、预期的事件与趋势、经济状况及其他未来条件。

Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of RadNet’s and iCAD’s control. RadNet’s, iCAD’s and RadNet’s actual results and financial condition following the proposed transaction may differ materially from those indicated in the forward-looking statements as a result of various factors.

由于前瞻性陈述与未来相关，因此它们受到固有的不确定性、风险和难以预测的环境变化的影响，其中许多因素超出RadNet和iCAD的控制范围。受各种因素的影响，RadNet和iCAD在拟议交易后的实际结果和财务状况可能与前瞻性陈述中所示的内容存在重大差异。

None of RadNet, iCAD or any of their respective directors, executive officers, or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur, or if any of them do occur, what impact they will have on the business, results of operations or financial condition of RadNet or iCAD.

RadNet、iCAD 或其各自的董事、高级管理人员或顾问均不提供任何陈述、保证或担保，即任何前瞻性声明中所表达或暗示的事件将实际发生，或者即使其中任何事件确实发生，它们将对 RadNet 或 iCAD 的业务、经营结果或财务状况产生何种影响。

Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on RadNet’s and iCAD’s businesses, the proposed transaction and the ability to successfully complete the proposed transaction and realize its expected benefits. Risks and uncertainties that could cause results to differ from expectations include, but are not limited to: (1) the termination of or occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement or the inability to complete the proposed transaction on the anticipated terms and.

如果任何风险和不确定性发展为实际事件，这些发展可能会对RadNet和iCAD的业务、拟议交易以及成功完成拟议交易并实现其预期效益的能力产生重大不利影响。可能导致结果与预期不同的风险和不确定性包括但不限于：(1) 合并协议终止或发生任何可能导致合并协议终止的事件、变化或其他情况，或无法按预期条款完成拟议交易。

Forward-looking statements included herein are made only as of the date hereof and, except as required by applicable law, neither RadNet nor iCAD undertakes any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent.

本文件中包含的前瞻性陈述仅截至本文日期作出，除非适用法律要求，RadNet和iCAD均不承担更新任何前瞻性陈述或本通讯中的任何其他信息的义务，无论由于新信息、未来发展或其他原因，亦不对其中出现的任何不准确或遗漏进行更正。

All forward-looking statements in this communication are qualified in their entirety by this cautionary statement..

本通讯中所有的前瞻性陈述均受此警示性声明的全面约束。